Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults.

Enterotoxigenic Escherichia coli (ETEC) is the leading cause of bacterial diarrhea in young children in developing countries. The safety and immunogenicity of a killed, oral ETEC vaccine consisting of whole cells plus recombinantly produced cholera toxin B subunit (rCTB) was evaluated in Egypt, which is endemic for ETEC diarrhea. Seventy-four healthy Egyptian adults (21-45 years old) were randomized and received two doses of the ETEC/rCTB vaccine (E003) or placebo 2 weeks apart. The frequency of adverse events after either dose did not differ by treatment group, and no severe adverse events were reported. After vaccination, peripheral blood IgA B cell responses to CTB (100%) and to vaccine colonization factor antigens CFA/I (94%), CS4 (100%), CS2 (81%), and CS1 (69%) were significantly higher than response rates for the placebo group. These favorable results in Egyptian adults indicate that the ETEC/rCTB vaccine is a promising candidate for evaluation in younger age groups in this setting.

[1]  J. Holmgren,et al.  Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. , 1998, Vaccine.

[2]  C. Czerkinsky,et al.  Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  N. Binsztein,et al.  Characterization of monoclonal antibodies against putative colonization factors of enterotoxigenic Escherichia coli and their use in an epidemiological study , 1993, Journal of clinical microbiology.

[4]  C. Wennerås,et al.  Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. , 1993, Vaccine.

[5]  C. Wennerås,et al.  Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine , 1992, Infection and immunity.

[6]  A. Siitonen,et al.  Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine , 1991, The Lancet.

[7]  C. Wennerås,et al.  Development of an Oral Vaccine Against Enterotoxigenic Escherichia coli Diarrhea , 1991 .

[8]  J. Holmgren,et al.  Recombinant fusion protein for simple detection of Escherichia coli heat-stable enterotoxin by GM1 enzyme-linked immunosorbent assay , 1990, Journal of clinical microbiology.

[9]  D. Sack,et al.  Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. , 1988, The Journal of infectious diseases.

[10]  H. Dupont,et al.  The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. , 1986, The American journal of tropical medicine and hygiene.

[11]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[12]  A. Svennerholm,et al.  Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens , 1982, Infection and immunity.